Rheumatology
From the Journals
Diabetes drug class appears to reduce recurrent gout flares
Previously associated with a lower incidence of gout, SGLT2 inhibitors for the first time also appear to reduce gout flare recurrence and excess...
News from the FDA/CDC
FDA approves canakinumab for gout flares
Canakinumab is the first biologic in the U.S. approved for treating gout flares.
Guidelines
ACR releases guideline for managing ILD in patients with rheumatic disease
“Guidance was needed for which tests to use for screening and monitoring this particular disease,” said lead author Sindhu R. Johnson, MD, PhD....
From the Journals
Slight weight gain, no blood pressure increase with low-dose steroids for RA
People with rheumatoid arthritis who take long-term, low-dose glucocorticoids do not appear to have significant...
Latest News
Rheumatology trials seem vulnerable to unblinding: Report
In an analysis of 14 published randomized controlled clinical trials of common rheumatology drugs, most had a high estimated risk for inadvertent...
Conference Coverage
Structural changes may separate axial psoriatic arthritis from axial spondyloarthritis
Approximately two-thirds of patients met criteria for both conditions, but imaging data show distinctions.
Feature
Axial spondyloarthritis: Does visibility with x-rays make a difference in management?
“Axial spondyloarthritis is one disease, and whether it is radiographic or nonradiographic makes zero difference in the management of the patient...
Feature
Diagnosing chronic back pain: When to suspect axial spondyloarthritis
Worldwide, the average time to diagnosis was found to be up to 6 years, but patient advocacy groups say the delay can be up to 10 years or more....
Latest News
Study validates use of new psoriatic arthritis prediction tool
To develop the tool, researchers evaluated 635 patients with psoriasis from a prospective longitudinal cohort study evaluating risk factors for...
Latest News
Gout: Suboptimal management a continuing problem
Pipeline drugs show promise but undertreatment, poor adherence reduce efficacy of current therapies.
From the Journals
Autoantibody against enteric nervous system protein linked to GI dysfunction in systemic sclerosis
If validated as a biomarker, antigephyrin autoantibodies could help identify patients at higher risk for GI symptoms like constipation.